Related Experiment Video
Updated: Aug 7, 2026
11:49
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents
J H Baron1, A H Gershlick, K Hogrefe
1Department of Medicine and Therapeutics, University of Leicester, Glenfield Hospital, UK.
Cardiovascular Research
|July 27, 2000
Summary
Coating polymer stents with c7E3-Fab (abciximab) effectively inhibits platelet deposition. This approach shows promise for developing drug-eluting stents to reduce stent thrombosis and restenosis.
Area of Science:
- Biomaterials science
- Cardiovascular research
- Pharmacology
Background:
- Stent thrombosis and in-stent restenosis are significant clinical challenges.
- c7E3-Fab (abciximab) targets platelet glycoprotein IIb/IIIa and smooth muscle cell alpha(v)beta3 receptors.
- Achieving high local concentrations of c7E3-Fab via stents could impact these processes.
Purpose of the Study:
- To investigate the adsorption and elution of c7E3-Fab on polymer-coated stents.
- To assess the effect of antibody-coated stents on platelet deposition in vitro.
- To evaluate antibody deposition in ex vivo human saphenous vein to predict clinical impact on thrombosis and restenosis.
Main Methods:
- Radioisotope techniques measured c7E3-Fab adsorption onto stents.
- In vitro perfusion circuits assessed antibody elution over 12 days.
- Platelet deposition was measured using 111-Indium labeled platelets after stent treatment.
Main Results:
- c7E3-Fab adsorption was concentration and time-dependent.
- Slow elution observed, with 53% remaining after 12 days.
- Stent treatment inhibited platelet deposition by 82.3% (P=0.018).
- c7E3-Fab deposited in the intima and media of ex vivo saphenous veins.
Conclusions:
- Passive adsorption of c7E3-Fab onto polymer-coated stents is feasible.
- The antibody elutes slowly and predictably from stents.
- Stent-based delivery of c7E3-Fab significantly inhibits platelet deposition, offering potential for reducing stent-related complications.
